Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19124343 | 0.88 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL19124221 | 0.88 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL19125174 | 0.86 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL19124204 | 0.86 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL19124149 | 0.85 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL19124581 | 0.85 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL19125089 | 0.85 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL19124230 | 0.85 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL19124243 | 0.85 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL19124157 | 0.85 | ADORA3 (1.00) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402798-B1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC (KR) | 2021-04-28 | — | — | EP | disclosed |
| US-10196396-B2 | Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof | HANDOK INC. (KR) | 2019-02-05 | — | — | US | disclosed |
| EP-3402798-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | Handok Inc. (KR) | 2018-11-21 | — | — | EP | disclosed |
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC. (KR) | 2017-07-20 | — | — | US | disclosed |
| WO-2017123058-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | HANDOK INC. (KR) | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196396-B2 | Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885 |
| US-20170204101-A1 | COMPOUNDS ANTAGONIZING A3 ADENOSINE RECEPTOR, METHOD FOR PREPARING THEM, AND MEDICAL-USE THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.